Legend Biotech USA
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Legend Biotech USA sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Legend Biotech USA: 2 sponsored US clinical trials, 1 recruiting.
Legend Biotech USA sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Large Cell Neuroendocrine Carcinoma of the Lung, with 1 trials.
Mid-pack sponsor footprint
Legend Biotech USA is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
NCT05680922
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT05539430
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
What is open in the Legend Biotech USA pipeline
1 recruiting of 2 indexed (50% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Large Cell Neuroendocrine Carcinoma of the Lung (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Legend Biotech USA: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Legend Biotech USA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Legend Biotech USA page
2 registered trials is a research-attention snapshot, not an endorsement of Legend Biotech USA or any single study.
- 1 of Legend Biotech USA's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Large Cell Neuroendocrine Carcinoma of the Lung is the condition Legend Biotech USA studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Large Cell Neuroendocrine Carcinoma of the Lung trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Legend Biotech USA pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.